M. Matsuo

p53 Adenoviral vector (Ad‐CMV‐p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model

A. Gotoh, C. Kao, N. Hinata, 2000, The journal of gene medicine.

Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells.

K. Sugimura, A. Gotoh, T. Shirakawa, 2001, International Journal of Radiation Oncology, Biology, Physics.

Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.

K. Sugimura, L. Chung, K. Hamada, 2007, Human gene therapy.

Combination with CD/5‐FC gene therapy enhances killing of human bladder‐cancer cells by radiation

A. Gotoh, N. Hinata, T. Shirakawa, 2003, The journal of gene medicine.

Drug‐resistant human bladder‐cancer cells are more sensitive to adenovirus‐mediated wild‐type p53 gene therapy compared to drug‐sensitive cells

K. Sugimura, A. Gotoh, C. Kao, 2001, International journal of cancer.

G6PD DEFICIENCY AND APPLICATION OF THE MPTP TECHNIQUE

T. Shirakawa, K. Nishiyama, M. Matsuo, 2001 .

Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling

T. Takumi, Y. Minami, M. Okada, 2009, Oncogene.

Vesicourethral sphincter dysfunction in ncx deficient mice with an increased neuronal cell number in vesical ganglia.

M. Hatano, T. Tokuhisa, S. Kojima, 2001, The Journal of urology.